List of Excipients in Branded Drug CIMETIDINE

Generic Drugs Containing CIMETIDINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA, Inc.	cimetidine	0093-8192	CARNAUBA WAX
Teva Pharmaceuticals USA, Inc.	cimetidine	0093-8192	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA, Inc.	cimetidine	0093-8192	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA, Inc.	cimetidine	0093-8192	FD&C BLUE NO. 1 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in CIMETIDINE?

# Of NDCs	Excipient
1	ALCOHOL
4	ALUMINUM OXIDE
1	BLUE 1
12	CARNAUBA WAX

Excipient Strategy and Commercial Opportunities for CIMETIDINE

Last updated: March 2, 2026

What are the fundamental excipient considerations for CIMETIDINE formulations?

CIMETIDINE, a histamine H2 receptor antagonist, is used primarily to reduce gastric acid secretion. Its formulations commonly include excipients that enhance stability, bioavailability, and patient tolerability. Available forms range from oral tablets to injectables. These formulations rely on excipient choices aligned with manufacturing processes, stability profiles, and delivery routes.

Typical excipients used in CIMETIDINE formulations

Excipients	Function	Usage Notes
Lactose monohydrate	Diluent	Ensures powder homogeneity
Microcrystalline cellulose	Binder and filler	Improves tablet integrity
Magnesium stearate	Lubricant	Facilitates manufacturing, prevents sticking
Gelatin or hypromellose	Capsule shell	Used in capsule formulations
Sodium bicarbonate or citric acid	Disintegrants	Enable tablet breakdown in gastric environment
Sodium phosphate buffers	pH stabilizers	Maintain stable pH for drug stability

Formulation-specific considerations

• Oral tablets: Lactose, microcrystalline cellulose, magnesium stearate, disintegrants (e.g., sodium bicarbonate), and film coating agents.

• Injectables: Aqueous buffers, stabilizers, preservatives, and isotonic agents compatible with intravenous delivery.

• Capsules: Gelatin shells with filling agents such as microcrystalline cellulose and diluents.

How do excipient choices impact CIMETIDINE's stability and manufacturability?

Excipient selection directly influences shelf life, bioavailability, and manufacturing efficiency. For CIMETIDINE:

• Stability: Excipients such as buffers prevent pH shifts that could degrade the active ingredient. Compatibility with CIMETIDINE’s chemical profile minimizes hydrolysis and oxidation.

• Absorption: Disintegrants facilitate rapid tablet breakup, enhancing onset of action. Using excipients that do not interfere with gastric pH is crucial.

• Manufacturability: Lubricants and flow agents like magnesium stearate aid in compression and prevent equipment issues.

What are the commercial opportunities derived from excipient innovation?

Innovations in excipient technology open pathways for new CIMETIDINE formulations and markets.

Opportunities include:

1. Extended-release formulations: Development employs matrix-forming excipients or controlled-release coatings, altering dosing frequency.

2. Enhanced bioavailability: Use of solubilizers or permeability enhancers in formulations can improve absorption, especially in pediatric or geriatric populations.

3. Redesigned capsules: Custom capsules incorporate innovative shell materials to improve stability or allow for combining CIMETIDINE with synergistic drugs.

4. Alternative delivery routes: Transdermal patches or buccal formulations require excipients facilitating absorption through skin or mucosa.

5. Patent protection: Novel excipient combinations or formulation techniques may extend patent life or restrict generic entry.

Market analysis

The global market for CIMETIDINE was approximately USD 110 million in 2021 ([2]). Despite decline due to safety concerns, niche markets in hospitals and emerging markets maintain demand. Innovation through excipient technology can create differential products suitable for resistant or unresponsive patient subsets.

What regulatory considerations influence excipient strategies for CIMETIDINE?

Regulatory agencies like FDA and EMA maintain strict excipient safety and compatibility standards.

• GRAS compliance: Excipients must be Generally Recognized As Safe (GRAS) or approved for specific routes and formulations.

• Compatibility testing: Emphasis on stability studies to prevent excipient-drug interactions.

• Labeling: Transparency about excipient ingredients is required, especially for allergens like lactose or gelatin.

• Quality Control: Consistency of excipient quality must meet pharmacopeial standards for purity and functionality.

Summary of strategic insights

• The choice of excipients in CIMETIDINE formulations influences product stability, bioavailability, manufacturing efficiency, and patient tolerability.

• Innovation opportunities include controlled-release matrices, bioavailability enhancers, and alternative delivery methods.

• Regulatory pathways require rigorous safety, stability, and compatibility assessments, shaping excipient selection and formulation development.

• Market prospects for CIMETIDINE-based products hinge on niche applications, improved formulations, and patent strategies.

Key Takeaways

• Excipient selection is central to optimizing CIMETIDINE formulations and extending product life cycles.
• Innovations, especially in controlled-release and alternative delivery systems, can open new market segments.
• Regulatory compliance remains a critical hurdle; adherence ensures smooth approval processes.
• Market potential persists in specialized applications despite overall decline in primary use.
• Strategic patenting of novel excipient combinations can protect product differentiation.

FAQs

1. What are the main challenges in formulating CIMETIDINE?
   Ensuring chemical stability and bioavailability while maintaining manufacturing efficiency.

2. How can excipient innovation improve CIMETIDINE’s therapeutic profile?
   Through controlled-release formulations, it improves dosing convenience and enhances patient adherence.

3. Are there safety concerns with excipients in CIMETIDINE formulations?
   Yes, especially allergenic excipients like gelatin or lactose, which require careful labeling and regulation compliance.

4. What regulatory hurdles affect excipient choices in CIMETIDINE?
   Meeting safety standards, stability requirements, and ensuring compatibility with the active pharmaceutical ingredient.

5. What market segments show growth potential for CIMETIDINE formulations?
   Hospital, niche, and emerging markets benefit from tailored, innovative formulations.

References

[1] International Pharmaceutical Excipient Best Practices, Pharmaceutical Technology. (2020).

[2] Market Research Future. (2022). Global Proton Pump Inhibitors Market Analysis.

[3] US Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Support for Transdermal and Topical Formulations.